IMC-F106C Regimen Versus Nivolumab Regimens in Previously Untreated Advanced Melanoma (PRISM-MEL-301)
Clinical trial NCT06112314 · RECRUITING
Trial details
- NCT number
- NCT06112314
- Sponsor
- Immunocore Ltd
- Status
- RECRUITING
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2024-06-05
- Primary completion
- 2027-10-16
- Enrollment
- 680
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.